New nanomaterials for regenerative medicine is to be discussed at Pharmaceutical Nanotechnology conference

(Nanowerk News) Nanotechnology is a multidisciplinary scientific field that is currently undergoing explosive development. Nano-enhanced medicines are opening new opportunities for therapeutic delivery and targeting, technology is also allowing agents that previously could not be used effectively as conventional formulations due to poor bioavailability or drug instability to advance into clinical development. However, there are still a number of concerns remaining concerning toxicological aspects and ethical implications.
SMi is proud to present their Pharmaceutical Nanotechnology: Applications & Commercialisation conference, taking place in London on 29th and 30th June, 2011.
Key Presentations Include:

The business case for nanotechnology

Thomas Keller, Director, Open Innovation, GlaxoSmithKline

Miniaturisation and modelling of beads milling

Mostafa Nakach, Head of Pharmaceutical Engineering Group, Sanofi-Aventis R&D

Investigation of chitosan nanoparticle formulations

Michael Keller, Senior Fellow, siRNA Project Leader, Technical Research and Development (TRD), Novartis Pharma

Enabling oncology drug development with nanotechnology

Henry Havel, Senior Research Fellow, Product Research and Development, Eli Lilly and company

Industry partnering opportunities, open innovation, one solution

Peter Luke, Senior Director, R&D Business Development, Worldwide Business Development, Pfizer

For more information and to download the brochure visit
Source: SMI Group